Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
57.21
+0.19 (0.33%)
Oct 10, 2025, 4:00 PM EDT - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts that cover Kymera Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $61.65, which forecasts a 7.76% increase in the stock price over the next year. The lowest target is $44 and the highest is $79.
Price Target: $61.65 (+7.76%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 8 | 8 |
| Buy | 6 | 7 | 7 | 7 | 8 | 8 |
| Hold | 4 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $53 → $63 | Buy | Maintains | $53 → $63 | +10.12% | Oct 1, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $53 → $68 | Strong Buy | Maintains | $53 → $68 | +18.86% | Sep 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $70 | Strong Buy | Maintains | $60 → $70 | +22.36% | Sep 18, 2025 |
| Barclays | Barclays | Buy Initiates $60 | Buy | Initiates | $60 | +4.88% | Sep 17, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $70 | Buy | Initiates | $70 | +22.36% | Sep 16, 2025 |
Financial Forecast
Revenue This Year
76.31M
from 47.07M
Increased by 62.11%
Revenue Next Year
56.44M
from 76.31M
Decreased by -26.04%
EPS This Year
-3.49
from -2.98
EPS Next Year
-4.17
from -3.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 154.3M | 113.7M | |||
| Avg | 76.3M | 56.4M | |||
| Low | 42.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 227.9% | 49.0% | |||
| Avg | 62.1% | -26.0% | |||
| Low | -9.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.60 | -3.29 | |||
| Avg | -3.49 | -4.17 | |||
| Low | -3.84 | -6.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.